Go to contents

THE DONG-A ILBO Logo

Open Menu Close Menu Open Search Bar
검색창 닫기

Global Expansion (Celltrion)

Celltrion’s Remsima Takes 95% of Singapore Market, Leads Key Asian Nations

Dong-A Ilbo | Updated 2026.11.19
Panoramic view of Celltrion headquarters. Courtesy of Celltrion
Celltrion announced on the 19th that it is expanding its sales performance while maintaining high market shares for autoimmune disease and anticancer therapies in major Asian countries.

The company’s flagship “Remsima” product line has secured an overwhelming lead in Singapore with a market share of 95%. The anticancer therapies Herzuma and Truxima are also maintaining the No. 1 market share in key countries such as Hong Kong, Thailand, and Malaysia. Based on the sales network secured through its local direct sales strategy, Celltrion is also expanding market entry for subsequent biosimilar products.

According to pharmaceutical market research firm IQVIA, as of the second quarter of this year, the market shares of the autoimmune disease therapy Remsima (ingredient name: infliximab) product line (IV·SC) were 95% in Singapore, 83% in Hong Kong, and 75% in Malaysia. All three countries rank first in market share. In particular, in Singapore, the company has secured such a high market share that it accounts for most of the market for this product category.

Performance has also continued in anticancer therapies. The breast and gastric cancer therapy Herzuma (ingredient name: trastuzumab) recorded market shares of 67% in Hong Kong, 59% in Thailand, and 52% in Malaysia, maintaining a leading position in each market.

Growth in Thailand was especially notable. Herzuma’s market share in Thailand increased by 17 percentage points from the previous quarter to 59%. With a sharp rise in share in just one quarter, the company expanded its sales base in the local market.

The hematologic cancer therapy Truxima (ingredient name: rituximab) also recorded a 92% market share in Singapore. It maintained leading positions with 78% in Thailand and 41% in Hong Kong. In Singapore, Truxima has achieved a market share of over 90%, following Remsima.

The growth of later-launched products is also drawing attention. The metastatic colorectal and breast cancer therapy Vegzelma (ingredient name: bevacizumab) ranked fourth in market share in Malaysia in the fourth quarter of last year, but rose to first place in the first quarter of this year. It maintained its leading position in the second quarter with a 25% share.

Celltrion explained that this performance reflects the effectiveness of the direct sales system built around its local subsidiaries. The company attributed the results to operating sales strategies tailored to each country’s pharmaceutical tender system and the needs of medical institutions, while simultaneously ensuring stable drug supply and conducting academic activities for healthcare professionals.

The company stated that in the Asian market, where tender-based procurement has a high weight, it has increased the market share of its key products by leveraging the sales capabilities of local subsidiaries to secure supply contracts and strengthening cooperative relationships with medical institutions.

Building on the sales performance of existing products, the company is also accelerating the market entry of higher-margin subsequent biosimilars. Since the end of last year, Celltrion has successively launched the allergy treatment Omlyclo (ingredient name: omalizumab) and the autoimmune disease therapy Steqima (ingredient name: ustekinumab) in markets including Singapore and Malaysia.

At the end of this month, it plans to launch Vegzelma in Hong Kong, and in December, it will introduce the bone disease therapy Stoboclo (ingredient name: denosumab) in Thailand. In February next year, it plans to launch the ophthalmic disease treatment Aidenzelt (ingredient name: aflibercept) in Singapore and Omlyclo in Thailand.

Celltrion intends to use the local sales networks and medical institution relationships it has established with existing products to shorten the time required for subsequent products to gain a foothold in the market and to increase sales in the Asian region.

A Celltrion official said, “Key product lines, including Remsima, are strengthening their market presence in Asia by maintaining high market shares,” and added, “By leveraging the direct sales capabilities of our local subsidiaries and the value of our brands, we will promote the early market establishment of high-profit follow-on product lines and continue to drive performance growth in the Asian region.”

Hwang So-young

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News